tetano
Editor, Senior Moderator
Stem Cell Res Ther
. 2022 Mar 25;13(1):126.
doi: 10.1186/s13287-022-02794-3.
Human placenta-derived amniotic epithelial cells as a new therapeutic hope for COVID-19-associated acute respiratory distress syndrome (ARDS) and systemic inflammation
Amirhesam Babajani[SUP] #[/SUP][SUP] 1 [/SUP], Kasra Moeinabadi-Bidgoli[SUP] #[/SUP][SUP] 1 [/SUP], Farnaz Niknejad[SUP] #[/SUP][SUP] 1 [/SUP], Hamidreza Rismanchi[SUP] #[/SUP][SUP] 1 [/SUP], Sepehr Shafiee[SUP] #[/SUP][SUP] 1 [/SUP], Siavash Shariatzadeh[SUP] #[/SUP][SUP] 1 [/SUP], Elham Jamshidi[SUP] 1 [/SUP], Mohammad Hadi Farjoo[SUP] 1 [/SUP], Hassan Niknejad[SUP] 2 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), has become in the spotlight regarding the serious early and late complications, including acute respiratory distress syndrome (ARDS), systemic inflammation, multi-organ failure and death. Although many preventive and therapeutic approaches have been suggested for ameliorating complications of COVID-19, emerging new resistant viral variants has called the efficacy of current therapeutic approaches into question. Besides, recent reports on the late and chronic complications of COVID-19, including organ fibrosis, emphasize a need for a multi-aspect therapeutic method that could control various COVID-19 consequences. Human amniotic epithelial cells (hAECs), a group of placenta-derived amniotic membrane resident stem cells, possess considerable therapeutic features that bring them up as a proposed therapeutic option for COVID-19. These cells display immunomodulatory effects in different organs that could reduce the adverse consequences of immune system hyper-reaction against SARS-CoV-2. Besides, hAECs would participate in alveolar fluid clearance, renin-angiotensin-aldosterone system regulation, and regeneration of damaged organs. hAECs could also prevent thrombotic events, which is a serious complication of COVID-19. This review focuses on the proposed early and late therapeutic mechanisms of hAECs and their exosomes to the injured organs. It also discusses the possible application of preconditioned and genetically modified hAECs as well as their promising role as a drug delivery system in COVID-19. Moreover, the recent advances in the pre-clinical and clinical application of hAECs and their exosomes as an optimistic therapeutic hope in COVID-19 have been reviewed.
Keywords: ARDS; Amniotic membrane; COVID-19; Epithelial stem cells; Exosome; Immunomodulation; Regenerative medicine; SARS-CoV-2.
. 2022 Mar 25;13(1):126.
doi: 10.1186/s13287-022-02794-3.
Human placenta-derived amniotic epithelial cells as a new therapeutic hope for COVID-19-associated acute respiratory distress syndrome (ARDS) and systemic inflammation
Amirhesam Babajani[SUP] #[/SUP][SUP] 1 [/SUP], Kasra Moeinabadi-Bidgoli[SUP] #[/SUP][SUP] 1 [/SUP], Farnaz Niknejad[SUP] #[/SUP][SUP] 1 [/SUP], Hamidreza Rismanchi[SUP] #[/SUP][SUP] 1 [/SUP], Sepehr Shafiee[SUP] #[/SUP][SUP] 1 [/SUP], Siavash Shariatzadeh[SUP] #[/SUP][SUP] 1 [/SUP], Elham Jamshidi[SUP] 1 [/SUP], Mohammad Hadi Farjoo[SUP] 1 [/SUP], Hassan Niknejad[SUP] 2 [/SUP]
Affiliations
- PMID: 35337387
- DOI: 10.1186/s13287-022-02794-3
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), has become in the spotlight regarding the serious early and late complications, including acute respiratory distress syndrome (ARDS), systemic inflammation, multi-organ failure and death. Although many preventive and therapeutic approaches have been suggested for ameliorating complications of COVID-19, emerging new resistant viral variants has called the efficacy of current therapeutic approaches into question. Besides, recent reports on the late and chronic complications of COVID-19, including organ fibrosis, emphasize a need for a multi-aspect therapeutic method that could control various COVID-19 consequences. Human amniotic epithelial cells (hAECs), a group of placenta-derived amniotic membrane resident stem cells, possess considerable therapeutic features that bring them up as a proposed therapeutic option for COVID-19. These cells display immunomodulatory effects in different organs that could reduce the adverse consequences of immune system hyper-reaction against SARS-CoV-2. Besides, hAECs would participate in alveolar fluid clearance, renin-angiotensin-aldosterone system regulation, and regeneration of damaged organs. hAECs could also prevent thrombotic events, which is a serious complication of COVID-19. This review focuses on the proposed early and late therapeutic mechanisms of hAECs and their exosomes to the injured organs. It also discusses the possible application of preconditioned and genetically modified hAECs as well as their promising role as a drug delivery system in COVID-19. Moreover, the recent advances in the pre-clinical and clinical application of hAECs and their exosomes as an optimistic therapeutic hope in COVID-19 have been reviewed.
Keywords: ARDS; Amniotic membrane; COVID-19; Epithelial stem cells; Exosome; Immunomodulation; Regenerative medicine; SARS-CoV-2.